KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $13.3 million.

  • Twist Bioscience's Share-based Compensation rose 1069.14% to $13.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $65.7 million, marking a year-over-year increase of 2667.84%. This contributed to the annual value of $64.5 million for FY2025, which is 2657.63% up from last year.
  • Per Twist Bioscience's latest filing, its Share-based Compensation stood at $13.3 million for Q4 2025, which was up 1069.14% from $16.1 million recorded in Q3 2025.
  • Twist Bioscience's Share-based Compensation's 5-year high stood at $22.5 million during Q1 2022, with a 5-year trough of -$2.3 million in Q4 2022.
  • For the 5-year period, Twist Bioscience's Share-based Compensation averaged around $13.4 million, with its median value being $12.8 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 11283.96% in 2022, then skyrocketed by 57397.85% in 2023.
  • Quarter analysis of 5 years shows Twist Bioscience's Share-based Compensation stood at $18.1 million in 2021, then tumbled by 112.84% to -$2.3 million in 2022, then surged by 573.98% to $11.0 million in 2023, then rose by 8.81% to $12.0 million in 2024, then grew by 10.69% to $13.3 million in 2025.
  • Its Share-based Compensation was $13.3 million in Q4 2025, compared to $16.1 million in Q3 2025 and $16.1 million in Q2 2025.